This document is a published patent application from the USPTO detailing a new class of compounds designed for use as contrast agents in diagnostic imaging, specifically computed tomography (CT) and magnetic resonance imaging (MRI). The application, identified as US20260083864A1, describes compounds of general formula (I), their metal chelates (including Gd3+ complexes), methods of preparation, and their application in diagnostic imaging.

While patent applications are not regulations, they represent potential future innovations that could impact the pharmaceutical and medical device sectors. Companies involved in diagnostic imaging, drug development, and medical device manufacturing should be aware of this filing as it may indicate emerging technologies or competitive intellectual property in the field. No immediate compliance actions are required, but monitoring patent landscapes is crucial for strategic planning and R&D.